



DOCKET NO. TJU-2503 (SCH01.NP001)

COPY OF PAPERS
ORIGINALLY FILED

#18/K.T.
9/13
PATENT
C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re application of:

SEP 11 2002

Ray S. Schneider

TECH CENTER 1600/2900

Serial No.: **09/435,249**

Group Art Unit: **1635**

Filed: **November 5, 1999**

Examiner: **M. Schmidt**

For: **Treatment Of Parkinson's Disease With Oligonucleotides**

I, Mark DeLuca, Registration No. 33,229, certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

On September 4, 2002

Mark DeLuca, Registration No: 33,229

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

AMENDMENT AND REQUEST FOR RECONSIDERATION

In response to the Office Action mailed June 5, 2002 in connection with the above-identified patent application, Applicant requests that the application be amended as follows.

In the Specification:

q q

Please replace the paragraph beginning on page 8, line 27 with the following paragraph:

These sequences were obtained by searching Genbank for the appropriate gene name.

These sequences were analyzed using an open reading frame finder program at the National Center for Biotechnology Information and is publicly available through the Internet at the world wide web at, for example, ncbi.nlm.nih.gov/cgi-bin/gorf/orfig. The initiation of translation site was found and a 21 base antisense molecule complementary to the region spanning 8 bases 5' to 13 bases 3' (-8 to